Application of fibroblast growth factor 17 protein and / or its activator in preparing drugs for treating Alzheimer's disease

By resuming the damage to neurons by beta-amyloid in Alzheimer's disease by using fibroblast growth factor 17 protein and/or its activator, the problem that existing therapeutic drugs cannot reverse disease progression is solved, and Al Effective treatment of Zheimer's disease shows the potential of FGF17 in novel protein drugs.

CN117838835BActive Publication Date: 2024-11-08JINAN UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410141628.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-02-01
Publication Date
2024-11-08
Estimated Expiration
2044-02-01

AI Technical Summary

Technical Problem

Existing Alzheimer's disease treatments cannot fundamentally reverse disease progression and have limited effectiveness in neuronal damage caused by beta-amyloid, leading to an urgent need to develop new therapeutic drugs.

Method used

Fibroblast growth factor 17 protein and/or its activator are used to restore the damage caused to neurons by β-amyloid β-amyloid through different concentrations of FGF17, enhance neuronal cell viability, and improve synaptic-related protein levels and neuronal protrusion length. .

Benefits of technology

Different concentrations of FGF17 can restore the reduction of neuronal cell viability, downregulation of synaptic-related protein levels and damage to neuronal protrusions caused by Aβ. It has the potential to become a new protein drug and provides an effective treatment plan for Alzheimer's disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117838835B_ABST
    Figure CN117838835B_ABST
Patent Text Reader

Abstract

The present invention discloses the use of fibroblast growth factor 17 protein and / or its activator in the preparation of a drug for treating Alzheimer's disease, and belongs to the field of biomedical technology. The present invention first discovered that different concentrations of FGF17 can restore the damage caused by Aβ to neurons, including cell viability, cell body state, synaptic growth, etc., and plays an important role in the treatment of Alzheimer's disease. Therefore, it has the potential to become a new type of protein drug different from existing protein or antibody drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to the use of fibroblast growth factor 17 protein and / or its activator in the preparation of drugs for treating Alzheimer's disease. Background Art

[0002] Alzheimer's disease (AD), also known as senile dementia, is the most common neurodegenerative disease, accounting for nearly three-quarters of dementia cases. Its typical clinical features include mood swings, memory loss, cognitive dysfunction, language dysfunction, and visual-spatial dysfunction, which seriously affect patients' social, professional and life. When Alzheimer's disease progresses to the late stage, it can cause serious symptoms such as malnutrition, multiple organ failure caused by neuronal necrosis, and even brain death.

[0003] It is reported that more than 47 million people suffer from Alzheimer's disease worldwide, and its incidence rate is rising sharply every year. In the United States, Alzheimer's disease is officially listed as the sixth leading cause of death. Although many basic studies have been conducted on the pathogenesis of Alzheimer's disease, the potential for translating promising discoveries into clinical treatments remains limited. In the past decade, there have been relatively few clinical trials for Alzheimer's disease, and the failure rate is as high as 99.6%. Currently approved drugs are mainly divided into two categories, namely cholinesterase inhibitors, including tacrine, donepezil, rivastine and galantamine, and NMDA receptor competitive inhibitors, namely memantine, which play a neuroprotective role by preventing neuronal loss and improving symptoms by helping to restore the function of damaged neurons. These drugs can only change the course of the disease, rather than acting on symptoms, and cannot fundamentally reverse the progression of the disease, so the development of new AD therapeutic drugs is particularly necessary and urgent.

[0004] Fibroblast growth factor 17 (FGF17) belongs to the FGF8 subfamily of the fibroblast growth factor family and is an autocrine / paracrine fibroblast growth factor. Structurally, FGF17 has heparin or heparin sulfate (HS) affinity and can bind to glycosylated HS chains extending from the transmembrane core protein. Functionally, FGF17 and FGF8 play a role in embryonic development, brain development and formation, and abdominal wall closure as midbrain-hindbrain junction organizers and isthmus organizers. There are currently no reports on the use of FGF17 in the treatment of Alzheimer's disease. Summary of the invention

[0005] The purpose of the present invention is to provide the use of fibroblast growth factor 17 protein and / or its activator in the preparation of drugs for treating Alzheimer's disease, so as to solve the problems existing in the above-mentioned prior art.

[0006] To achieve the above object, the present invention provides the following solutions:

[0007] The present invention provides use of fibroblast growth factor 17 protein and / or its activator in preparing a drug for treating Alzheimer's disease.

[0008] The present invention also provides the use of fibroblast growth factor 17 protein and / or its activator in preparing a medicine for treating neuron damage caused by beta-amyloid protein.

[0009] The present invention also provides a pharmaceutical composition comprising fibroblast growth factor 17 protein and / or an activator thereof.

[0010] The present invention also provides a pharmaceutical preparation, comprising the pharmaceutical composition and a pharmaceutically acceptable carrier.

[0011] Preferably, the pharmaceutical carrier is suitable for solid dosage form, liquid dosage form, paste dosage form or emulsion dosage form.

[0012] The present invention also provides the use of fibroblast growth factor 17 protein and / or its activator in preparing a drug for enhancing neuronal cell activity.

[0013] The present invention also provides the use of fibroblast growth factor 17 protein and / or its activator in preparing a drug for improving the level of synapse-related proteins.

[0014] The present invention also provides the use of fibroblast growth factor 17 protein and / or its activator in preparing a drug for increasing the length of neuronal processes.

[0015] Based on the above technical solution, the present invention has the following technical effects:

[0016] The present invention discovers for the first time that different concentrations of fibroblast growth factor 17 protein can restore the damage caused by β-amyloid protein to neurons, including cell viability, cell body state, synaptic growth, etc., and plays an important role in the treatment of Alzheimer's disease. Therefore, it has the potential to become a new type of protein drug that is different from existing protein or antibody drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0018] Figure 1 The figure shows the experimental results of different concentrations of FGF17 restoring the damage of Aβ to the viability of rat primary neuronal cells;

[0019] Figure 2The figure shows the experimental results of high and low concentrations of FGF17 restoring the inhibitory effect of Aβ on synaptic-related proteins in rat primary neuronal cells;

[0020] Figure 3 The figure shows the experimental results of high and low concentrations of FGF17 restoring the damaging effect of Aβ on the neurite outgrowth of rat primary neuronal cells;

[0021] Figure 4 The experimental results of high and low concentrations of FGF17 restoring the damage of Aβ to the number and length of processes of primary neurons in rats, where A is the average process length of neurons, B is the number of processes of each neuron, and C is the proportion of neurons with the longest process length exceeding 100 μm;

[0022] Figure 5 The figure shows the experimental results that high and low concentrations of FGF17 restored the damaging effects of Aβ on the cell bodies and processes of rat primary neuronal cells. DETAILED DESCRIPTION

[0023] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0024] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0025] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0026] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present application description and examples are exemplary only.

[0027] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0028] The technical solutions described in the present invention, unless otherwise specified, are all conventional solutions in the art, and the reagents or raw materials used, unless otherwise specified, are purchased from commercial channels or are publicly available.

[0029] Example 1

[0030] 1. Extraction of Primary Neurons

[0031] 1.1 One day before the experiment, the culture plate was coated with poly-lysine at a concentration of 0.0125 mg / mL and then placed in an ultra-incubator overnight. The next day, poly-lysine was recovered in the ultra-clean bench, and the coated culture plate was rinsed twice with sterile water and air-dried for later use.

[0032] 1.2 Place the ice box disinfected with 75% ethanol in the middle of the clean bench, place the culture dish containing D-hank's buffer on the ice box, arrange the sterilized surgical instruments in order, and place a small beaker containing 75% ethanol on one side of the clean bench.

[0033] 1.3 The bilateral cortices were obtained from newborn SD mice and then transferred to another culture dish containing D-hank's medium to remove the meninges and hippocampus.

[0034] 1.4 Transfer the separated cortex into a vial containing 2 mL of D-hank's buffer and cut the tissue into pieces of about 1 mm using curved scissors. 3 size.

[0035] 1.5 Add 1 mL of 25% trypsin to each vial, mix well by blowing with a pipette, and place in a 37°C incubator for digestion for 5 min. Then take out the vial, blow several times with a glass blowpipe, and continue to place in a 37°C incubator for digestion for 5 min.

[0036] 1.6 After digestion, add 5 mL of DMEM + 10% FBS medium to each vial to terminate digestion, and gently blow the tissue several times with a blowpipe to free the cells from the tissue.

[0037] 1.7 Use a pipette to transfer the suspension to a 200-mesh sieve, collect the filtrate that passes through the sieve, transfer the filtrate to a 15 mL centrifuge tube, and centrifuge at 1500 rpm for 5 min.

[0038] 1.8 After centrifugation, discard the supernatant, add 2 mL of DMEM + 10% FBS culture medium and gently blow the cell pellet to fully resuspend it.

[0039] 1.9 Take 20 μL of cell suspension and add it to 20 μL of trypan blue solution. Mix well by pipetting. Pipette the mixture into Countstar cell counting plate and use cell counter to detect cell concentration.

[0040] 1.10 The obtained cell resuspension was inoculated into the cell culture plate according to the ratio of 80,000 cells per well of 96-well plate, 400,000 cells per well of 24-well plate and 1 million cells per well of 6-well plate.

[0041] 1.11 6 hours after inoculation, discard the DMEM+10% FBS medium and replace it with Neurobasal+2% B27 medium.

[0042] 1.12 The culture medium was replaced on the 3rd day, during which the cell growth status was observed. The culture medium was used for various experiments on the 5th day.

[0043] 2.CCK8 Experiment

[0044] 2.1 80,000 primary neurons were plated into 96-well plates per well. The culture medium was replaced after 5 h and cultured in a 37°C incubator until the third day. The culture medium was replaced again and cultured for another 2 days.

[0045] 2.2 Dilute Aβ using Neurobasal + 2% B27 medium 1-42 and FGF17, so that the concentration of Aβ1-42 after dilution was 3 μM, and the concentration of FGF17 was 20 ng / mL, 50 ng / mL, 100 ng / mL and 500 ng / mL respectively. Carefully remove the medium of the 96-well plate and add the Aβ 1-42 and FGF17 medium and continue culturing in a 37°C incubator for 24 h.

[0046] 2.3 After 24 hours, remove the culture medium, add 100 μL of CCK8 reaction solution to each well, and place the well in a 37°C incubator for 2 hours to 4 hours in the dark.

[0047] 2.4 Use an ELISA reader to read the absorbance value at 450 nm and calculate the cell viability.

[0048] The experimental results show that different concentrations of FGF17 can restore the decreased neuronal cell viability caused by Aβ ( Figure 1 ).

[0049] 3. Western Blot Experiment

[0050] 3.1 Cell lysis

[0051] 3.1.1 Mix PIPA lysis buffer, protease inhibitor cocktail and PMSF in a ratio of 100:1, prepare and use immediately, and pre-cool on ice.

[0052] 3.1.2 Discard the culture medium in the culture dish and add 1 mL PBS to wash twice.

[0053] 3.1.3 Add an appropriate amount of lysis buffer according to the cell quantity, shake gently to allow the lysis buffer to fully soak the bottom of the dish, and place on ice for 30 minutes to fully lyse the cells.

[0054] 3.1.4 Use a scraper to scrape off the cells on the culture dish and transfer the lysate mixed with cells to a 1.5 mL EP tube.

[0055] 3.1.5 Centrifuge at 12000×g for 30 min in a centrifuge precooled to 4°C. Transfer the supernatant to a new 1.5 mL EP tube to obtain the total protein solution obtained by lysis and store it at -80°C.

[0056] 3.2 Protein concentration determination and sample preparation

[0057] 3.2.1 Use ultrapure water to dilute and prepare protein standard solutions with a concentration gradient of 0, 0.025, 0.05, 0.1, 0.2, 0.3, 0.4, and 0.5 mg / mL.

[0058] 3.2.2 Prepare BCA solution in the ratio of A solution: B solution = 50:1, mix well and set aside.

[0059] 3.2.3 Add 20 μL of gradient diluted protein standard solution to each well of the 96-well plate, and add 18 μL of ultrapure water and 2 μL of protein sample solution to the sample wells. Finally, add 200 μL of BCA solution to each 96-well well containing protein standard solution or sample.

[0060] 3.2.4 Place the 96-well plate in a 37°C incubator and incubate for 30 minutes. Use an ELISA reader with a wavelength of 570 nm to measure the absorbance, and use Excel to draw a standard curve and a trend line R. 2 The standard curve is usable only when the value is ≥0.995. Substitute the value of each sample into the formula to calculate the concentration of each sample.

[0061] 3.2.5 Use the measured protein concentration to calculate the volume of protein sample solution required to prepare equal mass samples. Mix equal masses of protein sample solution, 5×SDS loading buffer and ultrapure water to make equal volumes of protein samples, and then denature the protein in a 100℃ water bath for 10 minutes.

[0062] 3.3Western blot

[0063] 3.3.1 Prepare SDS-polyacrylamide gel according to the molecular weight of the target protein. After the gel is completely solidified, add the sample and two-color pre-stained protein marker to the wells of the gel respectively.

[0064] 3.3.2 Add electrophoresis buffer to the assembled electrophoresis tank and start electrophoresis. First, adjust the voltage to a constant voltage of 60V for electrophoresis. After the sample is electrophoresed from the upper concentrated gel to the separation gel, adjust the voltage to 100V to separate the protein.

[0065] 3.3.3 According to the length and width of the gel, cut off the PVDF membrane of corresponding area and soak it in methanol for 2 minutes to activate the charge on the PVDF membrane.

[0066] 3.3.4 Take out the SDS-polyacrylamide gel after electrophoresis, assemble the parts of the transfer clamp in order, remove all bubbles between the PDVF membrane and the gel, and place it in the transfer clamp box.

[0067] 3.3.5 Place the assembled cartridge into the transfer tank, add pre-cooled transfer buffer, place the device on ice, transfer the membrane at a constant current of 235 mA, and set the transfer time according to the molecular weight of the target protein and the concentration of the SDS-polyacrylamide gel.

[0068] 3.3.6 After the transfer, take out the PDVF membrane and soak it in 5% skimmed milk powder in TBST solution. Block it at room temperature for 1.5 hours on a shaker at 20 rpm.

[0069] 3.3.7 Based on the position of the protein marker and the size of the target protein, cut the PDVF membrane into sections of different protein sizes and place them in marked boxes.

[0070] 3.3.8 Add the diluted primary antibodies into the antibody box respectively, immerse the membrane completely in the corresponding antibody dilution solution, shake on a 20rpm platform, and incubate at 4℃ for 12 to 16 hours.

[0071] 3.3.9 After incubation, remove the primary antibody diluent, add TBST and wash three times on a shaker at 80 rpm, each time for 10 min.

[0072] 3.3.10 According to the properties of the primary antibody, add an appropriate amount of secondary antibody and incubate on a shaker at 20 rpm for 2 hours.

[0073] 3.3.11 Remove the secondary antibody diluent, add TBST and wash three times on a shaker at 80 rpm, each time for 10 min.

[0074] 3.3.12 Evenly add ECL luminescent liquid on the membrane and develop it on a fluorescent imager.

[0075] The experimental results show that different concentrations of FGF17 can restore the downregulation of synaptic-related protein levels caused by Aβ ( Figure 2 ).

[0076] 4. Immunofluorescence

[0077] 4.1 Take out the culture medium of the slide inoculated with cells, discard the culture medium, and add 1 mL PBS to wash twice.

[0078] 4.2 Add 500 μL of room temperature 4% paraformaldehyde to each well and let stand for 30 minutes to fix the cells.

[0079] 4.3 Discard the paraformaldehyde, add 1 mL of PBS containing 2 mg / mL glycine to each well, and wash three times, each time for 5 minutes.

[0080] 4.4 Add 500 μL of 0.2% Tritonx-100 permeabilization solution to each well, incubate for 10 min, discard the permeabilization solution, and wash the cells 3 times with 1 mL of PBS per well, each time for 5 min.

[0081] 4.5 Add 500 μL of immunostaining blocking solution and incubate for 1 hour.

[0082] 4.6 Discard the blocking solution, dilute the primary antibody with primary antibody diluent at a ratio of 1:200, add 250uL of primary antibody diluent to each well, and incubate at 4℃ overnight.

[0083] 4.7 Remove the primary antibody diluent and use 1 mL of 0.05% Tween 20 and 1% BSA PBS cleaning solution for each well, wash 5 times, 5 minutes each time.

[0084] 4.8 Prepare the secondary antibody solution at a ratio of 1:200 based on the corresponding properties of the primary antibody. Add 250 μL of the secondary antibody solution to each well and incubate in the dark for 1 hour.

[0085] 4.9 Remove the secondary antibody and wash each well with 1 mL of 0.05% Tween 20 and 1% BSA PBS solution for 5 times, each time for 5 minutes.

[0086] 4.10 Add 250 μL of DAPI dye solution to each well, incubate for 10 min, then add 1 mL of PBS to each well and wash 5 times, 5 min each time.

[0087] 4.11 Mark the cell name, treatment method, date and name on the slide, take 5 μL of anti-fluorescence quenching sealing solution on the slide, pick up the slide and place the cells face down on the slide with sealing solution, and add nail polish to the connection between the slide and the slide to fix the slide.

[0088] 4.12 Observe and take pictures using LSM 900 laser confocal microscope.

[0089] The experimental results show that after the addition of Aβ treatment, the average length of neuronal processes was significantly shortened, the proportion of cells with the longest process length exceeding 100μm was significantly reduced, and the number of neuronal processes also decreased. Different concentrations of FGF17 can effectively alleviate the damage of Aβ to neurons ( Figure 3 , 4 ).

[0090] 5. Scanning electron microscopy

[0091] 5.1 Discard the culture medium in the culture dish, wash the slides twice with PBS, add 2.5% glutaraldehyde, and fix at room temperature for 2-3 hours or at 4°C overnight.

[0092] 5.2 Remove the fixative and wash twice with PBS, 10 min each time.

[0093] 5.3 Dehydrate with 30%, 50%, 70%, 80%, 90%, and 100% ethanol in a gradient manner, 5-8 dishes each time, and repeat dehydration with 100% ethanol 2-3 times.

[0094] 5.4 Transfer the sample to a critical point dryer for critical point drying, and stick the dried sample on a copper table and spray gold.

[0095] 5.5 Use a scanning electron microscope for observation and photography.

[0096] The experimental results show that after Aβ treatment, the neuron cell bodies became rough and the neurites were significantly shortened. After adding different concentrations of FGF17, the neuron cell bodies became smooth and the neurites were significantly increased ( Figure 3 , 4 ).

[0097] FGF17 is an endogenous secretory protein with a small molecular weight that is easy to produce and purify in vitro. The protein is highly expressed in the mammalian brain and is not easily recognized and rejected by the host's immune system.

[0098] In summary, the present invention found that FGF17 can restore the decreased neuronal cell viability caused by Aβ, restore the down-regulation of synapse-related protein levels caused by Aβ, alleviate the damage of Aβ to neurons, restore the smoothness of neuronal cell bodies, and significantly increase the length of processes, and can be used to prepare drugs for the treatment of Alzheimer's disease.

[0099] Obviously, the above embodiments of the present invention are merely examples for clearly explaining the present invention, and are not intended to limit the implementation methods of the present invention. For ordinary technical users in the relevant field, other different forms of changes or modifications can be made on the basis of the above description. It is not necessary and impossible to list all the implementation methods here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.

Claims

1. Application of fibroblast growth factor 17 protein in the preparation of drugs for restoring the decreased neuronal cell viability caused by Aβ.

2. Application of fibroblast growth factor 17 protein in the preparation of drugs for restoring the down-regulation of synapse-related protein levels caused by Aβ.

3. Application of fibroblast growth factor 17 protein in the preparation of drugs for restoring the shortened neuronal process length caused by Aβ.